

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
20 August 2020 (20.08.2020)



(10) International Publication Number
WO 2020/165788 A1

(51) International Patent Classification:

C07D 487/08 (2006.01) A61P 19/02 (2006.01)
A61K 31/506 (2006.01) A61P 37/00 (2006.01)
A61P 17/00 (2006.01)

(21) International Application Number:

PCT/IB2020/051128

(22) International Filing Date:

12 February 2020 (12.02.2020)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

62/806,180 15 February 2019 (15.02.2019) US

(71) Applicant: **PFIZER INC.** [US/US]; 235 East 42nd Street,
New York, New York 10017 (US).

(72) Inventors: **YANG, Xiaojing**; c/o Pfizer Inc., 445 Eastern
Point Road, Building 98, Groton, Connecticut 06340 (US).
SAMUEL, Amanda Patrice Surajhie; c/o Pfizer Inc., 610
Main Street, Cambridge, Massachusetts 02139 (US).

(74) Agent: **ZIELINSKI, Bryan C.**; Pfizer Inc., 235 East 42nd
Street, MS 235/9/S20, New York, New York 10017 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR,
TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(54) Title: CRYSTALLINE PYRIMIDINYL-3,8-DIAZABICYCLO[3.2.1]OCTANYLMETHANONE COMPOUND AND USE THEREOF



(57) Abstract: The present invention discloses a novel crystalline form of ((S)-2,2-difluorocyclopropyl)-((1R,5S)-3-(2-((1-methyl-1H-pyrazol-4-yl)amino)-pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone free base, pharmaceutical composition containing the same, preparations thereof and uses thereof (Formula (I)).

WO 2020/165788 A1